Kim A P Meeuwis1, Alison Potts Bleakman2, Peter C M van de Kerkhof1, Yves Dutronc3, Carsten Henneges4, Lori J Kornberg5, Alan Menter6. 1. a Department of Dermatology , Radboud University Nijmegen Medical Center , Nijmegen , Netherlands. 2. b Eli Lilly and Company , Indianapolis , IN , USA. 3. c Lilly France , Neuilly sur Seine , France. 4. d Lilly Deutschland GmbH , Bad Homburg , Germany. 5. e Syneos Health , Raleigh , NC , USA. 6. f Baylor University Medical Center , Dallas , TX , USA.
Abstract
BACKGROUND: Psoriatic lesions in the genital area (GenPs) can cause considerable physical and emotional distress. To increase physician awareness, we estimated the GenPs prevalence among patients with psoriasis. METHODS: An English language literature search was performed. Articles reporting GenPs prevalence met the search criteria and were included. Because GenPs is rarely reported in demographics of prospective clinical trials, GenPs prevalence and baseline demographics of patients with and without GenPs in two prospective randomized phase 3b trials (NCT02561806 and NCT02634801) involving patients with moderate-to-severe psoriasis are reported. RESULTS: Overall, 600 references were screened. Eighteen articles met the search criteria. Patient populations were highly heterogeneous across articles. Broadly, the presence of GenPs was either physician-reported (physical examinations) or patient-reported (questionnaires). In the literature, GenPs prevalence at the time of reporting ranged from 7% to 42% and the prevalence of GenPs at any time during the course of psoriasis ranged from 33% to 63%. In the two prospective clinical trials, the prevalence of GenPs at the time of enrollment was 35-42%. CONCLUSION: A substantial proportion of patients experience genital lesions at some time during the course of psoriasis. Increased awareness of GenPs prevalence may drive improved assessment and treatment.
BACKGROUND: Psoriatic lesions in the genital area (GenPs) can cause considerable physical and emotional distress. To increase physician awareness, we estimated the GenPs prevalence among patients with psoriasis. METHODS: An English language literature search was performed. Articles reporting GenPs prevalence met the search criteria and were included. Because GenPs is rarely reported in demographics of prospective clinical trials, GenPs prevalence and baseline demographics of patients with and without GenPs in two prospective randomized phase 3b trials (NCT02561806 and NCT02634801) involving patients with moderate-to-severe psoriasis are reported. RESULTS: Overall, 600 references were screened. Eighteen articles met the search criteria. Patient populations were highly heterogeneous across articles. Broadly, the presence of GenPs was either physician-reported (physical examinations) or patient-reported (questionnaires). In the literature, GenPs prevalence at the time of reporting ranged from 7% to 42% and the prevalence of GenPs at any time during the course of psoriasis ranged from 33% to 63%. In the two prospective clinical trials, the prevalence of GenPs at the time of enrollment was 35-42%. CONCLUSION: A substantial proportion of patients experience genital lesions at some time during the course of psoriasis. Increased awareness of GenPs prevalence may drive improved assessment and treatment.
Entities:
Keywords:
Genital psoriasis; clinical trials; literature search; prevalence
Authors: Juan Ortiz-Alvarez; Juan Carlos Hernández-Rodríguez; Julián Conejo-Mir Sánchez; Román Barabash-Neila Journal: Asian J Androl Date: 2022 Mar-Apr Impact factor: 3.285
Authors: Maximilian Christian Schielein; Linda Tizek; Barbara Schuster; Stefanie Ziehfreund; Tilo Biedermann; Alexander Zink Journal: Acta Derm Venereol Date: 2020-05-28 Impact factor: 3.875